Professor Sir Mark Caulfield will become the new CEO at Barts Life Sciences, an organisation with the aim to develop genomic care and support digital innovation, and help to combat health inequalities in the East London area.
Professor Sir Mark Caulfiel, commented on the appointment: “I’m delighted to be joining Barts Life Sciences to lead the delivery of a thriving life sciences cluster at the heart of Whitechapel.
“By bringing together the NHS, academia, industry, and health science organisations we will inspire, invent, and accelerate the adoption of cutting-edge medical innovations, that meet the needs of our local population and improve health for all.”
Previously Professor Sir Mark Caulfield acted as the Chief Scientist for Genomics England and will now step down from the role on the 31st July, but will continue in his role as Professor of Clinical Pharmacology at Queen Mary University of London.
Dame Alwen Williams DBE, Group Chief Executive, Barts Health NHS Trust, added: “It’s fantastic to have Mark come on board to lead Barts Life Sciences. Having someone with his expertise and experience as well as passion and commitment to driving science and healthcare forwards will not only benefit the organisation but the people of East London and beyond.”
In his new role as CEO Professor Sir Mark Caulfield will be working with Professor Rakesh Uppal, Director of Barts Life Sciences and Sven Bunn, Programme Director of Barts Life Sciences.
